RecruitingPhase 2NCT06018896

Vitamin C to Quality of Life in Patients With Terminal Stage Pancreatic Cancer

Sponsor

Fudan University

Enrollment

20 participants

Start Date

Aug 25, 2023

Study Type

INTERVENTIONAL

Conditions

Metastatic Pancreatic Cancer Terminal Cancer

Summary

The purpose of this study is to evaluate the efficacy of vitamin C in improving the quality of life for metastatic pancreatic cancer patients who are resistant to chemotherapy.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study tests whether high-dose intravenous vitamin C can improve quality of life for patients with terminal metastatic pancreatic cancer whose cancer has progressed after two rounds of chemotherapy. **You may be eligible if...** - You are between 18 and 80 years old - You have confirmed metastatic pancreatic adenocarcinoma - Your cancer has progressed after two lines of chemotherapy - You have adequate organ function and at least one measurable tumor - Your expected survival is at least 1 month **You may NOT be eligible if...** - You have another active cancer - Your cancer type is not adenocarcinoma - You are pregnant or breastfeeding - You have G6PD deficiency (a genetic enzyme condition that makes high-dose vitamin C dangerous) - You have kidney failure or require dialysis - You have serious gut inflammation (pancreatitis, cholecystitis, etc.) Talk to your doctor to see if this trial is right for you.

This is a simplified summary. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Print for Your Doctor Check Your Eligibility

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAscorbate

For patients with baseline serum Vitamin C concentration \< 65 μmol/L, intravenous Vitamin C 10 g × 7 days, intravenous Vitamin C 4 g × 7 days, intravenous Vitamin C 2 g × 7 days, followed by continuously 900 mg/day, three times a day, orally. For patients with baseline serum Vitamin C concentration ≥ 65 μmol/L, continuously 900 mg/day, three times a day, orally.

Locations(1)

Shanghai Cancer Center

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06018896

Related Trials

A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

NCT074092727 locations

A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors

NCT051439701 location